Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...

Children who inherit genetic mutations from parents with early-onset Alzheimer’s typically show signs of dementia at the same ...

Eli Lilly & Co. is tapping the US investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase of ...

The Washington University trial comes as part of a larger platform study which hopes to understand if Alzheimer's disease can ...

Discover how small biotechs are innovating in the weight loss therapy market with new treatments targeting unique mechanisms ...

Scientists are testing an experimental anti-amyloid antibody in people expected to develop early-onset Alzheimer's.

Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for MASH and cardiometabolic diseases.

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

The FDA last month accepted the application for subcutaneous Leqembi for maintenance dosing, with a target action date of ...

A US university has launched a prevention trial examining the use of Eli Lilly’s investigational ... determine if the investigational monoclonal antibody remternetug can remove plaques of ...